You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Progression-free survival

Showing 9951 - 9975 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HNSCC Trial in Worldwide (Eftilagimod alpha, Pembrolizumab)

Recruiting
  • HNSCC
  • Birmingham, Alabama
  • +28 more
Nov 29, 2022

Renal Cell Carcinoma Trial (Neoadjuvant Lenvatinib, Neoadjuvant Pembrolizumab, Radical nephrectomy, IVC thrombectomy,

Not yet recruiting
  • Renal Cell Carcinoma
  • Neoadjuvant Lenvatinib
  • +3 more
  • (no location specified)
Dec 23, 2022

Metastatic Castration-resistant Prostate Cancer Trial in China (olaparib, abiraterone acetate)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Beijing, China
  • +35 more
Aug 9, 2022

Lung Tumors, Pulmonary Metastasis Trial in Beijing, Guangzhou, Shanghai (Pulmonary Radiofrequency Ablation System and the

Unknown status
  • Lung Neoplasms
  • Pulmonary Metastasis
  • Pulmonary Radiofrequency Ablation System and the Disposable Pulmonary Radiofrequency Ablation Catheter
  • Beijing, Beijing, China
  • +2 more
Oct 20, 2021

Advanced Malignancies Trial in Beijing (Recombinant Humanized Monoclonal Antibody MIL95)

Recruiting
  • Advanced Malignancies
  • Recombinant Humanized Monoclonal Antibody MIL95
  • Beijing, China
    Beijing Cancer Hospital
Feb 14, 2022

Colon Cancer Trial (mFOLFIRINOX-FOLFIRI intensified chemo, FOLFOX or CAPOX adjuvant chemo)

Not yet recruiting
  • Colon Cancer
  • mFOLFIRINOX-FOLFIRI intensified chemotherapy
  • FOLFOX or CAPOX adjuvant chemotherapy
  • (no location specified)
Sep 6, 2022

Locally Advanced or Metastatic Solid Tumors, Genes, BRCA 1 Trial in Worldwide (Avelumab, Talazoparib)

Active, not recruiting
  • Locally Advanced or Metastatic Solid Tumors
  • Genes, BRCA 1
  • Palo Alto, California
  • +89 more
Jan 18, 2023

Biliary Tract Cancer, Programmed Cell Death 1 Ligand 1 Gene Mutation, Targeted Molecular Therapy Trial in Beijing (Camrelizumab,

Not yet recruiting
  • Biliary Tract Cancer
  • +3 more
  • Beijing, Beijing, China
    Beijing Friendship Hospital
Jan 20, 2021

COVID-19 Pneumonia Trial in Ann Arbor (Uproleselan)

Recruiting
  • COVID-19 Pneumonia
  • Ann Arbor, Michigan
    The University of Michigan
Dec 6, 2021

Non-hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (ZX-101A)

Recruiting
  • Non-hodgkin Lymphoma
  • +2 more
  • Gilbert, Arizona
  • +5 more
Jan 14, 2022

Metastatic Pancreatic Cancer Trial in Long Branch, New Brunswick (Folfirinox alternating with Gemcitabine-nab-Paclitaxel)

Recruiting
  • Metastatic Pancreatic Cancer
  • Folfirinox alternating with Gemcitabine-nab-Paclitaxel
  • Long Branch, New Jersey
  • +1 more
Jun 8, 2021

Solid Tumor, Breast Cancer, Cancer of Head and Neck Trial in Worldwide (RO6874281, Trastuzumab, Cetuximab)

Completed
  • Solid Tumor
  • +2 more
  • Tucson, Arizona
  • +25 more
Nov 21, 2022

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Trial (Asciminib, Nilotinib)

Not yet recruiting
  • Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
  • (no location specified)
Jul 11, 2022

Recurrent Cervical Carcinoma, Metastatic Cervical Cancer Trial in Guangzhou, Guanzhou (SHR-1210, Apatinib)

Active, not recruiting
  • Recurrent Cervical Carcinoma
  • Metastatic Cervical Cancer
  • Guangzhou, Guangdong, China
  • +2 more
Sep 24, 2021

Acute Myeloid Leukemia Trial in Nanjing (Venclexta 100 MG Oral Tablet)

Recruiting
  • Acute Myeloid Leukemia
  • Venclexta 100 MG Oral Tablet
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital with Nanjing Medical University
Jun 11, 2023

Retrospective Study of Brachytherapy

Recruiting
  • Brachytherapy
  • +6 more
  • Brachytherapy
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Feb 6, 2022

Solid Tumor, Adult Trial in United States (IMSA101, Immune checkpoint inhibitor (ICI), Immuno-oncology (IO) therapy)

Recruiting
  • Solid Tumor, Adult
  • Scottsdale, Arizona
  • +5 more
Apr 14, 2022

Hepatocellular Carcinoma (HCC) Trial in Worldwide (Tislelizumab)

Completed
  • Hepatocellular Carcinoma (HCC)
  • Hefei, Anhui, China
  • +64 more
Jul 20, 2022

Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory

Recruiting
  • Relapsed or Refractory Acute Myeloid Leukemia
  • +2 more
  • Duarte, California
  • +1 more
Mar 14, 2023

NSCLC, Anemia, Cancer Trial in Worldwide (Darbepoetin alfa, Placebo)

Terminated
Has Results
  • Non-Small Cell Lung Cancer
  • +3 more
  • Darbepoetin alfa
  • Placebo
  • Anniston, Alabama
  • +566 more
Nov 4, 2022

Colorectal Cancer Metastatic Trial (Olinvacimab added to Capecitabine)

Not yet recruiting
  • Colorectal Cancer Metastatic
  • Olinvacimab added to Capecitabine
  • (no location specified)
Aug 30, 2021

Colorectal Cancer Trial in United States (Cetuximab, Neratinib)

Withdrawn
  • Colorectal Cancer
  • Gainesville, Florida
  • +11 more
Oct 26, 2021

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (FGFR Inhibitor

Completed
Has Results
  • Advanced Lymphoma
  • +5 more
  • FGFR Inhibitor AZD4547
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Jun 8, 2021

Idiopathic Pulmonary Fibrosis Trial in Beijing (AK3280, Placebo)

Not yet recruiting
  • Idiopathic Pulmonary Fibrosis
  • Beijing, Beijing, China
    China-Japan Friendship Hospital
Jul 19, 2022

Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer Trial in Duarte (radiation, procedure, other)

Active, not recruiting
  • Recurrent Prostate Cancer
  • +4 more
  • stereotactic body radiation therapy
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Sep 21, 2021